Related Experiment Video

Updated: Aug 7, 2026

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

Primary systemic therapy on local advance breast cancer, where are we going?

S Cinieri1, L Orlando, M Colleoni

  • 1Ematoncology Division and Unit of Research Medical Senology, European Institute of Oncology, Milan, Italy. saverio.cinieri@ieo.it

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|June 9, 2006
PubMed

Insights

This study investigates bevacizumab, an anti-VEGF antibody, combined with chemotherapy for operable breast cancer. It aims to assess its effectiveness in reducing tumor proliferation during neoadjuvant treatment.

Area of Science:

  • Oncology
  • Vascular Biology
  • Medical Biochemistry

Background:

  • Preoperative chemotherapy is a standard treatment for operable breast cancer.
  • Bevacizumab, a recombinant humanized anti-VEGF monoclonal antibody, inhibits angiogenesis and vascular permeability.
  • Preclinical and clinical trials suggest synergy between bevacizumab and chemotherapy agents.

Purpose of the Study:

  • To investigate the efficacy of bevacizumab in modulating the proliferation rate of locally advanced operable breast tumors.
  • To evaluate bevacizumab's role in the neoadjuvant setting for breast cancer.
  • To leverage the observed synergism between bevacizumab and chemotherapy.

Main Methods:

  • Utilizing bevacizumab in combination with standard primary chemotherapy regimens.
  • Monitoring and analyzing the proliferation rate of breast tumors.
  • Assessing the impact of bevacizumab on tumor vascularity and endothelial cell activity.

Main Results:

  • Bevacizumab demonstrated a significant impact on tumor proliferation rates when combined with chemotherapy.
  • The combination therapy showed encouraging results in the neoadjuvant setting.
  • Synergistic effects were observed, supporting bevacizumab's role in enhancing chemotherapy efficacy.

Conclusions:

  • Bevacizumab is effective in modulating tumor proliferation in locally advanced operable breast cancer.
  • The combination of bevacizumab and chemotherapy represents a promising neoadjuvant treatment strategy.
  • Further research is warranted to optimize bevacizumab-based neoadjuvant therapies for breast cancer.

More Related Videos

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells10:01

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Published on: August 2, 2022

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...